Copie à publier aux annexes au Moniteur belgeVolet B après dépôt de l'acte au greffe Au verso : Nom et signature (pas applicable aux actes de type "Mention"). ayant pouvoir de représenter la personne morale à l'égard des tiers Mentionner sur la dernière page du Volet B : Au recto : Nom et qualité du notaire instrumentant ou de la personne ou des personnes Greffe Moniteur belge au Réservé Mod PDF 19.01 N° d'entreprise : 0455317604 Nom (en entier) : CLARIANT PLASTICS & COATINGS (BELGIUM) SA (en abrégé) : Forme légale : Société anonyme Adresse complète du siège Fond Jean Pâques 1 : 1348 Ottignies-Louvain-la-Neuve Objet de l'acte : DENOMINATION, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS) Ce jour, le dix-sept novembre deux mille vingt. (...) Devant Peter Van MELKEBEKE, notaire à Bruxelles (premier canton), exerçant sa fonction dans la société " Berquin Notaires ", ayant son siège à Bruxelles, avenue Lloyd George 11, S'EST REUNIE L'assemblée générale extraordinaire de la société anonyme " CLARIANT PLASTICS & COATINGS (BELGIUM) SA ", ayant son siège à 1348 Ottignies-Louvain-la-Neuve, Fond Jean Pâques 1, ci-après dénommée la " Société ". (...) Un administrateur peut représenter plusieurs de ses collègues et émettre, en plus de sa propre voix, autant de votes qu'il a reçu de B ijl ag en b ij he t B el gi sc h S ta at sb la d - 0 2/ 12 /2 02 0 - A nn ex es d u M on ite ur b el ge - suiteVolet B Au verso : Nom et signature (pas applicable aux actes de type "Mention"). ayant pouvoir de représenter la personne morale à l'égard des tiers Mentionner sur la dernière page du Volet B : Au recto : Nom et qualité du notaire instrumentant ou de la personne ou des personnes Moniteur belge Réservé au Mod PDF 19.01 procurations.

 Strong past performance demonstrates that our strategy and execution are working  Megatrends and emerging opportunities align with our strengths  Innovation and services provide differentiation, incremental pricing power, and competitive advantage  Strong and proven management team driving growth and performance  Addressable market exceeds $40 billion 1 Schedule I Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S. ��PolyOne Investor Presentation�Bank of America Merrill Lynch �2014 US Basic Materials Conference�Boston, MA�December 11, 2014�� Forward-Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results Proof of Performance & 2015 Goals 32% Adjusted EPS CAGR from 2011 Innovation Drives Earnings Growth A Rich Pipeline of Opportunity Megatrends Aligned with Key End Markets Debt Maturities & Pension Funding – 9/30/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return PolyOne Core Values Why Invest In PolyOne? Appendix Q3 2014 Financial Highlights At a Glance�Global Color, Additives and Inks At a Glance�Global Specialty Engineered Materials At a Glance�Designed Structures and Solutions At a Glance�Performance Products and Solutions At a Glance�Distribution Plastics: Key to Future Sustainable Development Commitment to Operational Excellence Application Examples Slide Number 28 Anti-Counterfeiting Solutions 2012 Range Rover Evoque Interior Slide Number 31 Metal Replacement Solutions Next Generation Solar Charger High-Barrier Packaging Containers Aerospace Applications Non GAAP Rec - 11 5 14.pdf Sidoti & Company non-GAAP Rec

Mevopur™ Healthcare Functional Additives Mevopur™ Healthcare Functional Additives Mevopur™ Bio-based Polymer Solutions

Mevopur™ Healthcare Bio-based Polymer Solutions Mevopur™ Healthcare Functional Additives Mevopur™ Bio-based Polymer Solutions

expectations: US & Canada LATAM EMEA Asia • Net price benefit remains greater than wage and energy inflation • Clariant synergies and reduced administrative costs Q2 2 023 SEQUENTI AL SAL ES BY REGI ON Q 2 2 0 2 3 v s . Global Compact • Highlights ESG Performance, including ratings, awards, and certifications • Features increased carbon emissions disclosures, including Climate Change Scenario Analysis and Scope 3 emissions data • Outlines Sustainable Supplier Program, designed to enable supplier evaluation & collaboration • Reflects Great Place To Work® culture focused on safety, employee engagement and advancing diversity, equity and inclusion 20 22 SUSTAI NA BILI TY REPORT 19 Avient Confidential 20 • Virtual presentation to be held September 20, 2023 • Leadership will be conducting an investor-focused presentation around our sustainable solutions portfolio • Deep dive into how we enable customers to achieve their sustainability goals SUSTAINABILITY DAY 20 …are Growing at Twice the Rate as Conventional Products Sustainably-Branded Products… STAKEHOLD ER INFLUENC E D RI VES D EMA ND Consumers Are demanding recyclability and eco- conscious products Governments Are mandating changes through legislation, taxes, and regional accords Brand Owners Have committed to ambitious goals to achieve sustainability metrics 21 A P P E N D I X 24 Performance Additives 16% Pigments 12% TiO2 10% Dyestuffs 2% Polyethylene 11% Nylon 6% Polypropylene 5% Styrenic Block Copolymer 5% Other Raw Materials 33% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials 2022 pro forma results for the acquisition of Avient Protective Materials RA W MATERI AL BA SKET PEER COMPARISONS AVI ENT I S ASSET LI GHT Capex / Revenue 2023E (%) Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of August 17, 2023 Note: Avient reflects 2023 estimated revenue of $3,280 and estimated run-rate CAPEX of $110M. 26 3 2 3 3 4 4 3 4 5 5 7 7 9 10 A vi e n t K W R P P G F U L A V Y R P M F M C H U N C E E C L A S H H X L E M N S C L FR EE CA SH FLOW CONV ER SION Source: Peer data per Bloomberg as of August 17, 2023 Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA. Avient reflects 2023 adjusted EBITDA guidance of $525M and estimated run-rate CAPEX of $110M. 2023E (%) 27 79 89 83 83 78 75 90 81 76 72 68 63 53 11 A vi e n t K W R F U L P P G A V Y R P M F M C C E E C L A S H H X L H U N E M N S C L Avient Specialty Formulators Other Specialty / Chemical Companies MULTI PL E EX PANSION Source: Peer data per Bloomberg as of August 17, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $525M and closing share price of $37.07.

In millions, except per share data) In millions, except per share data) Condensed Consolidated Balance Sheets

G E N O M I C D I AG N O S T I C D E V I C E M A N U FAC T U R E R I N - V I T R O D I A G N O S T I C ( I V D ) D E V I C E MEVOPURTM Laser-Transmitting and Laser-Absorbing Pre-color Solution AV I E N T S O L U T I O N • Customized solutions - Quality-by-Design (QdB) approach • Optimized pigment / additive selection – good distribution in final part minimizes welding failure • Mitigated contamination and extractable risk on incoming raw material with control based on fingerprinting • Ensured uninterrupted supply from multiple ISO13485-2016 certified sites • Minimized risk of change with change control agreements W H Y AV I E N T K E Y R E Q U I R E M E N T S P R O D U C T I V I T Y & Q U A L I T Y • Good weldability, low rejection rate • Solutions in wide range of polymers, colors and transparency • Pre-tested ingredients to biocompatibility and extractable metals L E A R N M O R E https://www.avient.com/products/polymer-additives/performance-enhancement-additives/mevopur-functional-additives

MEVOPUR Colors for Ophthalmic Closures Application Bulletin_CN8.18-1 * 可根据要求提供FDA/EU合规信息 应用公告 用于眼科药物容器盖的 着色剂MEVOPUR™ 用于眼部（眼科）用药物容器盖的MEVOPUR标 准母粒系列产品符合美国眼科学会（AAO）的颜 色标准。

MEVOPUR Special Effect Colors Application Bulletin_CN MEVOPUR 特殊效果™ 应用公告 用于医疗器械和药品包装的效果着色剂 多年来，通过笔式设备和吸入器等器械自行给药 已成为常态。 MEVOPUR中使用的成分已经过测试，符合支持 医疗器械和药品包装应用的行业标准。

PHARMACEUTICAL PACKAGING OEM V I A L S , B O T T L E S & C O N T A I N E R S • Raw materials pre-tested to USP 661.1 and ICHQ3D guidelines • Stabilization during molding and sterilization processes for both opaque and transparent polymer materials • Certified formulations available globally • Offered pre-tested raw materials and produced in an ISO 13485 certified site, minimizing risk across the pharmaceutical value chain • Delivered specialized formulated solutions to meet stringent pharmaceutical packaging requirements • Provided global formulations transferrable from our three ISO 13485 certified facilities Mevopur™ Healthcare Concentrates KEY REQUIREMENTS WHY AVIENT? AVIENT SOLUTION CERTIFICATION + AVAILABILITY LEARN MORE © 2021, Avient Corporation, All Rights Reserved https://www.avient.com/products/polymer-colorants/solid-color-masterbatches/mevopur-custom-colors-and-formulations